Abstract: OBJECTIVE To evaluate the safety and efficacy of selegiline combined with levodopa in the treatment of Parkinson’s disease(PD). METHODS Random controlled trails of selegiline combined with levodopa for PD were gathered from Cochrane Library, PubMed, CNKI, WanFang and VIP from their establishment to November 2014. Two reviewers independently screened the studies, extracted the data and assessed the quality according to the inclusion and exclusion criteria. The Meta-analysis was conducted with RevMan 5.3 software. RESULTS A total of 5 randomized controlled trials (RCTs) involving 1 158 PD patients were included. The results of Meta-analysis showed that compared with levodopa used alone, the total UPDRS scores, motor UPDRS scores and Webster scores of selegiline combined with levodopa were significantly bettertotal UPDRS scores: MD=-5.29, 95%CI(-7.65, -2.94), P<0.000 1; motor UPDRS scores: MD=-3.57, 95%CI(-5.32, -1.82), P<0.000 1; Webster scores: MD=-4.99, 95%CI(-7.15, -2.83), P<0.000 01. There were no significant differences of the death incidences and adverse events incidencesdeath incidences: OR=1.23, 95%CI(0.89, 1.69), P=0.22; adverse events incidences: OR=1.10, 95%CI(0.77, 1.57), P=0.60. CONCLUSION Selegiline combined with levodopa is for treating PD, and significantly improves the total UPDRS scores, motor UPDRS scores and Webster scores based on this systematic review.